EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study

José Antonio Baz, Claire B Ren, Christof Burgdorf, Christian Frerker, Ignacio Cruz-González, Joan Antoni Gómez, José Maria Hernândez, Pilar Jimenez, Ernest Spitzer, Pim Tonino, Pieter Vriesendorp, Nicolas van Mieghem iD und 4 weitere

Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 540-547

DOI: 10.1002/ccd.70675 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 31.05.2026. Verfasst von José Antonio Baz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Spain. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve Stenosis, Bioprosthesis, Aortic Valve. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biosensors Europe SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The EMPIRE I study assessed the early (30 days) safety and efficacy of a new fully repositionable delivery system (IMPERIA) for the commercially available ALLEGRA transcatheter aortic valve in patients with either severe native aortic stenosis or a degenerated surgical bioprosthesis.

Aim

To report the final 1‐year results of the EMPIRE I study.

Methods

EMPIRE I is a pre‐market, prospective, multi‐center, single‐arm study conducted at 11 centers in 3 European countries. There were independent data safety and clinical events committees and an independent echocardiographic core laboratory. In this analysis, VARC‐3 definitions of all clinical endpoints and echocardiographic parameters were employed.

Results

The study recruited 121 patients with severe native aortic stenosis and 16 with degenerated surgical bioprosthesis. At 1 year, the incidence of bioprosthetic valve dysfunction in the native population was 5.9%. No patients developed structural valve deterioration or endocarditis, and there were no patients with haemodynamic valve deterioration or bioprosthetic valve failure. In the valve‐in‐valve sub‐group, 2/14 (14.3%) patients had moderate patient prosthesis mismatch at 30 days with no evidence of new bioprosthetic valve dysfunction at 1 year. In the native population, new permanent pacemaker implantation was 14.3% at 30 days and remained unchanged at 1 year. Cardiovascular mortality was 6.8% in the native population and 0% in the valve‐in‐valve patients. At 1‐year, all‐cause mortality was 10.8% (95% CI 6.4%−17.8%) in the native aortic stenosis population and 0% in the valve‐in‐valve patients.

Conclusion

After 1 year of follow‐up, the results of the EMPIRE 1 study show excellent haemodynamic performance, a low rate of bioprosthetic valve dysfunction, and no bioprosthetic valve failure in patients treated with the ALLEGRATM trans‐catheter aortic valve implanted using the new IMPERIATM fully repositionable delivery system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisAortic Valve StenosisBioprosthesisAortic ValveCardiac CatheterizationHeart Valve Prosthesis ImplantationTranscatheter Aortic Valve ReplacementHumansFemaleTreatment OutcomeProsthesis DesignMaleProspective StudiesTime FactorsEuropeAged, 80 and overAgedProsthesis FailureHemodynamicsSeverity of Illness IndexRisk Factors

Stichwörter der Autor:innen

aortic valve stenosisself‐expanding heart valvetranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Servicio de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Spain.
  • Department of Cardiology, Cardiovascular Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Cardialysis, Rotterdam, The Netherlands.
  • Herz- und Gefäßzentrum, Bad Bevensen, Germany.
  • Department of Cardiology, Universitätsklinik Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
  • Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, IBSAL, CIBER CV, Salamanca, Spain.

ORCID-Profile: Nicolas van Mieghem

Förderung

  • Biosensors Europe SA

Zitieren

APA

Baz, J. A., Ren, C. B., Burgdorf, C., Frerker, C., Cruz-González, I., Gómez, J. A., Hernândez, J. M., Jimenez, P., Spitzer, E., Tonino, P., Vriesendorp, P., van Mieghem, N., Copt, S., Jönsson, A., Oldroyd, K. G., & Doll, N. (2026). Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study. Catheterization and Cardiovascular Interventions, 108(2), 540-547. https://doi.org/10.1002/ccd.70675

Vancouver

Baz JA, Ren CB, Burgdorf C, Frerker C, Cruz-González I, Gómez JA, et al. Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study. Catheterization and Cardiovascular Interventions. 2026;108(2):540-547. doi:10.1002/ccd.70675

BibTeX
@article{Baz2026,
  author = {Baz, José Antonio and Ren, Claire B and Burgdorf, Christof and Frerker, Christian and Cruz-González, Ignacio and Gómez, Joan Antoni and Hernândez, José Maria and Jimenez, Pilar and Spitzer, Ernest and Tonino, Pim and Vriesendorp, Pieter and van Mieghem, Nicolas and Copt, Samuel and Jönsson, Anders and Oldroyd, Keith G and Doll, Nicolas},
  title = {Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {108},
  number = {2},
  pages = {540--547},
  doi = {10.1002/ccd.70675}
}
Kostenlos starten →